Navigation Links
Epizyme, Inc. Announces Pricing of Initial Public Offering
Date:5/30/2013

CAMBRIDGE, Mass., May 30, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc. today announced the pricing of its initial public offering of 5,142,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, Epizyme has granted the underwriters a 30-day option to purchase up to an additional 771,300 shares of common stock at the same price to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on May 31, 2013 under the ticker symbol "EPZM."

The offering is expected to close on June 5, 2013, subject to customary closing conditions.

Citigroup, Cowen and Company and Leerink Swann LLC are acting as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. are acting as co-managers.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on May 30, 2013. The offering is being made only by means of a prospectus, copies of which may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at batprospectusdept@citi.com, or by phone at 1-800-831-9146; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, phone (631) 274-2806, fax (631) 254-7140; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at Syndicate@Leerink.com, or by phone at 1-800-808-7525.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Epizyme, Inc.
Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing).


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 Research ... Pipeline Database" newsletter to their offering. ... , , ... La Merie Publishing,s proprietary R&D Drug Pipeline Database provides 24/7 online ... therapeutic drugs on the market and on investigational drug candidates in ...
(Date:12/2/2016)... the largest share in the ECG Cables And ECG Leadwires ... remote monitoring ECG devices. On the other hand, the ... the highest growth rate during the forecast period. ... Company (U.S.), Medtronic plc ( Ireland ), Koninklijke ... Medical International Limited ( China ), held major ...
(Date:12/2/2016)... Quantum Radiology,s Mobile Breast Center (QR MBC) brings cutting-edge ... at the workplace, thereby maximizing convenience and compliance.  QR ... and SunTrust Bank, and community health groups to provide ... "I think it,s a great service for ... a mammogram without taking a large amount of time ...
Breaking Medicine Technology:
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering local frontline ... field of pain management. , The demand for supplemental training related to ...
(Date:12/2/2016)... Texas (PRWEB) , ... December 02, 2016 , ... Yisrayl ... that delves into how this current generation fits into Bible Prophecy. Yisrayl says this ... various facts pointing to this conclusion, showing how the details line up exactly with ...
Breaking Medicine News(10 mins):